AZN vs MRK
AstraZeneca PLC and Merck & Co., both Healthcare
Merck & Co. is the larger company at $358B against $266B. Over the past year MRK returned +77% against +3.4% for AZN. The RyuScore puts MRK ahead, 76 against 62 out of 100.
| Figure | AZN | MRK |
|---|---|---|
| Last close | $171 | $145 |
| Market cap | $266B | $358B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 115.3 |
| Dividend yield | n/a | 2.2% |
| 1-year return | +3.4% | +77% |
| 5-year return | +55% | +111% |
| RyuScoresector-relative, 1–10 | 62/100 | 76/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.